ABSTRACT
INTRODUCTION

40
Plasmodium falciparum malaria remains the worst parasitic disease in developing countries, 41 with nearly 200 millions cases and 800,000 deaths reported each year (27). Quinolines
42
(mefloquine, amodiaquine, chloroquine and quinine) and antifolate (pyrimethamine, 43 proguanil, sulfadoxine) have been the major antimalarial drugs in endemic areas for decades.
44
Nevertheless, the emergence of multidrug-resistant P. falciparum parasites has made these 45 drugs useless in many endemic areas. This situation was particularly threatening until the Artemisinin is isolated from a plant (Artemisia annua) that has been used for treating 52 fever for more than 2,000 years in Chinese traditional medicine. ART shows rapid 53 antimalarial activity, has few side effects, and is active against parasite strains that are 54 resistant to many traditional antimalarial drugs such as quinolines and antifolates. To reduce 55 the risk of drug resistance, ART and its derivatives are generally used in combination with 56 other antimalarial agents. Although it is still being debated whether there are parasites that 57 can be considered to have real resistance to ART, e.g., greatly increased half inhibitory 58 concentration (IC 50 ), delayed clearance of parasites has been reported (6, 16, 17). Delayed 59 clearance suggests that some parasites can survive ART treatment for a longer period of time 60 than expected, but they are killed by the drug eventually, raising the possibility of a unique 61 survival mechanism different from a classical drug-resistance phenotype.
62
To better understand how parasites circumvent ART action, we placed a P. falciparum 63 strain (F32-Tanzania) under ART pressure over a period of 3 years and selected an ART- 
72
MATERIALS AND METHODS
73
Parasites and parasite culture.
74
Mycoplasma-free F32-Tanzania strain was cultivated according to Trager and Jensen (24) 75 with modifications (2). Briefly, parasites were maintained in O + human red blood cells
76
(French Blood Bank) diluted to 2.5% hematocrit in RPMI supplemented with 5% human 77 serum (Invitrogen, San Diego, CA). Culture was maintained at 37°C with 5% CO 2 .
78
Parasitemia was checked each day and was not allowed to be over 10%. ART and chloroquine 79 diphosphate were purchased from Sigma-Aldrich (St. Louis, MO), and artesunate was 80 provided by Sanofi-Aventis (Labège, France).
81
Selection of ART-tolerant strain.
82
Parasites were adjusted to 5% to 7% parasitemia (asynchronous) and grown in the presence of
83
ART for 24 h. The medium was discarded and replaced by human serum-supplemented (20%) 84 drug-free RPMI. Parasitemia was monitored until it reached 5%. At this time, drug pressure 85 was reapplied. This discontinuous drug pressure (28) was applied for more than 3 years with a 86 starting ART dose of 10 nM to a maximum dose of 9 µM (Figure 1 ). 
102
(50 µl/0.25 µCi). The control parasite cultures devoid of drug were referred to 100% growth.
103
The plates were incubated under the same conditions for another 24 h and then submitted to a 104 freeze-thaw cycle to release nucleic acids that were collected on fiberglass filters. The filters
105
were dried and placed in vials containing 6 ml scintillation fluid (OptiphaseSupermix; Perkin-
106
Elmer). Tritium incorporation was determined using a β-counter (wallac 1450 microbeta® 107 trilux; Perkin-Elmer), and IC 50 was determined after plotting drug concentration against 108 radioactivity (2).
109
Survival assay.
110
This assay was performed to evaluate the ability of different strains to survive drug pressure.
111
A 5% parasitemia ring-form culture (2.5% hematocrit) was obtained using sorbitol with the Ct value of pfmdr1 using the 2 -∆∆Ct method (13) . Reference strains Dd2 (2-3 pfmdr1 155 copies) and FcM29 (one copy) were used as controls. Each reaction was performed in 156 triplicate and the experiment repeated three-times.
157
Regions of interest in the pfatp6 gene were amplified using four pairs of primers performed using the NIAID µArray Center mAdb Gateway.
178
Quantitative PCR.
179
To verify changes in expression for some genes from microarray analyses, we synchronized 
194
RESULTS
195
Selection of ART-tolerant parasites.
196
After 3 years of applying ART pressure, we selected a P. falciparum line from the strain F32-
197
Tanzania. Selection was performed during 3 years for more than 100 drug pressure cycles
198
( Fig. 1) . The chemosensitivity of the parasites was evaluated at the end of each step and did 7,000 fold of the initial IC 50 value (9.9 nM ± 1). In comparison to F32-Tanzania, the F32-
210
ART strain was also more tolerant to artesunate (2.6 µM and 9 µM), even though F32-ART 211 was never exposed to this compound. This tolerance appeared to be limited to ART and (Table 1) .
214
In parallel, isotopic evaluation of chemosensitivity was routinely performed over the before (day 0, the same as F32-Tanzania or 9.9nM± 1.0) and after (day 1000) drug selection 218 (9.9 nM ± 1.4), which was similar to that of F32-Tanzania strain (9.9 nM ± 1.0). parasites were present 24 h and 48 h after ART pressure (Fig. 3, B and C) . Twenty-four hours 239 after drug removal, late stages of the parasite were present in culture (Fig. 3D) as the cell 240 cycle was restored.
241
To further confirm that only ring forms were responsible for recrudescence, scheduled (9 µM/48 h) was assessed on late-stage parasites (24 to 30 h), all parasites were killed, and no 246 parasites were recovered (data not shown).
247
No association of reported drug-resistant markers with ART tolerance.
248
We monitored two reported molecular markers that have been associated with decreased (ART at 9 µM) did not alter the F32-ART recovery time (data not shown).
257
Transcriptome analysis.
258
Microarray analysis was carried out to determine transcriptional up and/or downregulation 
